Influenza A virus in swine is an acute respiratory disease that causes economic losses in pig production. Vaccinating the right animal at the right time can be an important consideration in helping provide reliable protection against the economic losses caused by IAV-S throughout the herd.
The use of key performance indicators, including average daily gain and variation (the spread of weights across a group of pigs), is essential in helping assess the success of IAV-S protocols.
Positive impact on key performance measures with Ingelvac Provenza
In a field study to assess the performance benefit of Ingelvac Provenza on commercial growing pigs challenged with IAV-S, investigators set out to determine benefits to piglet performance in two separate challenge groups of pigs vaccinated between 3 and 5 days of age in the face of maternal antibodies.1
To determine the difference in weight gain between piglets vaccinated with Ingelvac Provenza and those left unvaccinated after challenge with a contemporary IAV-S at either 10 weeks or 15 weeks of age.
Investigators: C. Goodell, S. Playter, B. Fergen, R. Plazola (Iowa State University)
Method: Pigs were challenged with a contemporary heterologous IAV-S at either 10 or 15 weeks of age and performance was compared to unvaccinated cohorts.
Significant improvement in ADG
Pigs that were vaccinated with Ingelvac Provenza™ at 3 to 5 days of age and then challenged with IAV-S at either 10 or 15 weeks of age had:
- significantly more weight gain post-challenge than non-vaccinates
- reduced variation than non-vaccinated cohorts
Study group 1: Improvement in ADG in pigs challenged at 10 weeks of age
ADG was significantly higher in vaccinates than non-vaccinates post-challenge, with vaccinates gaining 0.36 pounds more per day through week one (P < 0.001) and 0.27 pounds more per day through week two (P ≤ 0.003) compared with non-vaccinates.
Vaccinates gained 4.4 pounds more than non-vaccinates for the three weeks following challenge
Study group 2: Improvement in ADG in pigs challenged at 15 weeks of age
ADG post-challenge was significantly higher, with vaccinates gaining an average of 0.13 pounds more per day from Day 1 through Day 14 (end of study) (P ≤ 0.041).
The 15-week challenge pigs also showed reduced variation in weight.
Variation seen as the tighter grouping of the interquartile range in the vaccinates (blue) versus non-vaccinates (gray).
Ingelvac Provenza for swine protection
Ingelvac Provenza™ is a bivalent live attenuated influenza vaccine that demonstrates broad cross-protection against the ever-evolving threat of IAV-S. This in-field evaluation supports Ingelvac Provenza as a strong foundation for respiratory health.
For more information on how Ingelvac Provenza can help bring measurable value to your herd’s health, visit IngelvacProvenza.com.
References: 1. Goodell C, Playter S, Fergen B, Plazola R. Performance benefit of Ingelvac Provenza on commercial growing pigs challenged with IAV-S. In: Allen D. Leman Swine Conference; Sept. 15-18, 2018; St. Paul, MN. Poster.
Partner. Protect. Perform.
Ingelvac Provenza is a trademark of Boehringer Ingelheim Vetmedica GmbH.
©2018 Boehringer Ingelheim Vetmedica, Inc. POR-1118-PRO1018 18234